Envoy Medical
COCH

$3.27

2.51%

Market Cap: $64.1M

About: Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.

Employees: 34

Healthcare Orthopedic, Prosthetic & Surgical Appliances & Supplies

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

18% more funds holding

Funds holding: 17 [Q1] → 20 (+3) [Q2]

0.23% less ownership

Funds ownership: 6.16% [Q1] → 5.93% (-0.23%) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

42% less capital invested

Capital invested by funds: $4.72M [Q1] → $2.74M (-$1.97M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8.50

160%

upside

Avg. target

$8.63

164%

upside

High target

$8.75

168%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Ascendiant Capital Edward Woo 38% 1-year accuracy 18 / 48 met price target	168%upside $8.75	Buy Maintained	3 Sept 2024
Ascendiant Capital Edward Woo 38% 1-year accuracy 18 / 48 met price target	160%upside $8.50	Buy Initiated	24 Jun 2024

See Analyst Rankings

Financial journalist opinion

Envoy Medical Awarded Patent for Recharge System used with Implantable Battery

Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss

Envoy Medical Awarded Patent for Recharge System used with Implantable Battery

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

The Dow Jones index closed higher by more than 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update

Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim ® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year

Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update

Bipartisan Senate Bill Seeks to Clarify that Implanted Active Middle Ear Hearing Devices are Prosthetics, Not Hearing Aids, Making Them Eligible for Medicare Coverage

Envoy Medical's FDA-Approved Esteem® Fully Implanted Active Middle Ear Hearing Device May Now Have an Opportunity to be a Coverable Benefit

Bipartisan Senate Bill Seeks to Clarify that Implanted Active Middle Ear Hearing Devices are Prosthetics, Not Hearing Aids, Making Them Eligible for Medicare Coverage

Envoy Medical Announces Inclusion in the Russell Microcap Index

WHITE BEAR LAKE, MN, July 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that FTSE Russell has selected the Company's shares for inclusion in its Microcap Index. The inclusion became effective at the close of market on Friday, June 28, 2024.

Envoy Medical Announces Inclusion in the Russell Microcap Index

Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024.

Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

Envoy Medical Announces Inclusion in the MSCI USA Micro Cap Index

WHITE BEAR LAKE, MN, June 06, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that MSCI has selected the Company's shares for inclusion in its MSCI USA Micro Cap Index. The inclusion became effective at the close of market on Friday, May 31, 2024. The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 constituents with an average market cap of $122 million at April 30, 2024. A wide range of microcap ETFs follow this benchmark and may reweight their holdings over the coming weeks for changes that occurred in this Index effective as of May 31.

Envoy Medical Announces Inclusion in the MSCI USA Micro Cap Index

Envoy Medical Is Pursuing Filling A Hearing Industry Void

Envoy Medical is a hearing device company that offers fully implantable devices for people with moderate to severe hearing loss. The company's second device, Acclaim, has been granted Breakthrough Device status and is about to begin clinical trials for FDA approval. Envoy's devices offer advantages such as no external device, no cleaning required, no risk of costly replacement, and 24/7 usage.

Envoy Medical Is Pursuing Filling A Hearing Industry Void

Envoy Medical Reports First Quarter 2024 Results

The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant.

Envoy Medical Reports First Quarter 2024 Results

ROSEN, A LONGSTANDING LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH

NEW YORK , April 20, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Envoy Medical, Inc. (NASDAQ: COCH) resulting from allegations that Envoy may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Envoy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH

See News Rankings